Neuronetics (NSDQ:STIM) posted first-quarter results today that beat the revenue consensus on Wall Street and matched on earnings. The Malvern, Pa.-based company reported losses of -$7.9 million, or -31¢ per share, on sales of $12.3 million for the three months ended March 31, 2021, for a sales growth of 7.08% compared with Q1 2020. Earnings per […]
Neuronetics
Neuronetics up on Street-beating Q3 results despite losses
Neuronetics (NSDQ:STIM) posted third-quarter results today that beat the consensus on Wall Street. The Malvern, Penn.-based company reported losses of $3.4 million, or -18¢ per share, on sales of $12.4 million for the three months ended Sept. 30, for a sales loss of -22.2% compared with Q3 2019. Earnings per share were -18¢, 11¢ ahead of […]
Neuronetics rises on Street-beating Q2
Neuronetics (NSDQ:STIM) shares ticked up today on second-quarter losses that managed to top the consensus forecast. The Malvern, Pa.-based psychiatric disorder treatment developer posted losses of $-7.8 million, or -41¢ per share, on sales of $9.7 million for the three months ended June 30, 2020, for a -9.5% bottom-line slide on a sales decline of -41.2%. […]
Neuronetics slides on missed Q1 projections, withdraws 2020 guidance
Neuronetics (NSDQ:STIM) posted first-quarter results that missed the consensus forecast on Wall Street. The Malvern, Penn.-based company reported losses of $12.6 million, or -68¢, on sales of $11.5 million for the three months ended March 31, for a bottom-line sales loss of -9.8% compared with Q1 2019. Earnings per share were -68¢, 16¢ behind The Street, […]
Neuronetics, Obalon Therapeutics get PPP loans
Neuronetics (NSDQ:STIM) and Obalon Therapeutics (NSDQ:OBLN) are the latest companies to announce that they entered into loans under the Paycheck Protection Program (PPP). The U.S. Small Business Association administers the PPP as part of the Coronavirus Aid, Relief and Economic Security (CARES) Act. Under the PPP, 75% of the loan proceeds must be used for payroll purposes, […]
Neuronetics president and CEO stepping down
Neuronetics (NSDQ:STIM) recently announced that president and CEO Christopher Thatcher would be stepping down, effective immediately. Thatcher also resigned as director of the board of directors and his employment is expected through May 1. He will continue to provide transition services and advice to the company. Neuronetics said that Thatcher’s resignation was a mutual agreement and […]
Neuronetics stocks up on Street-beating Q4 results
Neuronetics (NSDQ:STIM) this week posted fourth-quarter results that beat the consensus forecast on Wall Street. The Malvern, Penn.-based company reported profits of $3 million, or -41¢ per share, on sales of $17.4 million for the three months ended Dec. 31, 2019, for a bottom-line sales growth of 11% compared with Q4 2018. Earnings per share were […]
Neuronetics shares sink on Q3 losses
Neuronetics (NSDQ:STIM) shares were down today on third-quarter results that came up short of the consensus forecast. The Malvern, Pa.–based company — which makes a transcranial magnetic stimulation system to treat major depressive disorder — posted losses of -$6.9 million, or -37¢ per share, on sales of $16 million for the three months ended Sept. 30, […]
Neuronetics inks deal with TMS provider for NeuroStar depression device
Neuronetics (NSDQ:STIM) said today that it entered into a partnership with Success TMS to offer Neuronetics’ NeuroStar advanced therapy system as its preferred transcranial magnetic stimulation device across six states. The NeuroStar system is designed to use strong magnetic fields to stimulate areas of the brain associated with mood in the treatment of patients with […]
Neuronetics updates patient tracking system
Neuronetics (NSDQ:STIM) today announced the launch of a patient data management system designed to simplify administrative tasks and enable doctors to spend more time on patient care. The TrakStar Plus system builds on the Malvern, Penn.-based company’s TrakStar Cloud platform, designed to help physicians track patients implanted with Neuronetics’ NeuroStar device. Neurostar uses strong magnetic […]
Cutera snags Vyaire Medical’s Mowry for CEO | Personnel Moves, July 9, 2019
Cutera (NSDQ:CUTR) said today that it snagged Vyaire Medical CEO David Mowry to be its new CEO, effective immediately. The aesthetic device maker in January fired president & CEO James Reinstein after the company missed expectations for its 2018 top line, naming COO Jason Richey as interim chief executive. Mowry led Tornier to a $3.3 billion […]
